Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A (CMT1A)

2019 | journal article. A publication with affiliation to the University of Göttingen.

Jump to: Cite & Linked | Documents & Media | Details | Version history

Cite this publication

​Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A (CMT1A)​
Prukop, T.; Stenzel, J.; Wernick, S.; Kungl, T.; Mroczek, M.; Adam, J. & Ewers, D. et al.​ (2019) 
PlOS ONE14(1) art. e0209752​.​ DOI: https://doi.org/10.1371/journal.pone.0209752 

Documents & Media

journal.pone.0209752.pdf2.2 MBAdobe PDF

License

Published Version

Attribution 4.0 CC BY 4.0

Details

Authors
Prukop, Thomas; Stenzel, Jan; Wernick, Stephanie; Kungl, Theresa; Mroczek, Magdalena; Adam, Julia; Ewers, David; Nabirotchkin, Serguei; Nave, Klaus-Armin; Hajj, Rodolphe; Cohen, Daniel; Sereda, Michael W.
Abstract
The most common type of Charcot-Marie-Tooth disease is caused by a duplication of PMP22 leading to dysmyelination, axonal loss and progressive muscle weakness (CMT1A). Currently, no approved therapy is available for CMT1A patients. A novel polytherapeutic proof-of-principle approach using PXT3003, a low-dose combination of baclofen, naltrexone and sorbitol, slowed disease progression after long-term dosing in adult Pmp22 transgenic rats, a known animal model of CMT1A. Here, we report an early postnatal, short-term treatment with PXT3003 in CMT1A rats that delays disease onset into adulthood. CMT1A rats were treated from postnatal day 6 to 18 with PXT3003. Behavioural, electrophysiological, histological and molecular analyses were performed until 12 weeks of age. Daily oral treatment for approximately 2 weeks ameliorated motor deficits of CMT1A rats reaching wildtype levels. Histologically, PXT3003 corrected the disturbed axon calibre distribution with a shift towards large motor axons. Despite dramatic clinical amelioration, only distal motor latencies were improved and correlated with phenotype performance. On the molecular level, PXT3003 reduced Pmp22 mRNA overexpression and improved the misbalanced downstream PI3K-AKT / MEK-ERK signalling pathway. The improved differentiation status of Schwann cells may have enabled better long-term axonal support function. We conclude that short-term treatment with PXT3003 during early development may partially prevent the clinical and molecular manifestations of CMT1A. Since PXT3003 has a strong safety profile and is currently undergoing a phase III trial in CMT1A patients, our results suggest that PXT3003 therapy may be a bona fide translatable therapy option for children and young adolescent patients suffering from CMT1A.
Issue Date
2019
Journal
PlOS ONE 
ISSN
1932-6203
Language
English

Reference

Citations


Social Media